E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Hypertrophic cardiomyopathy: The first century 1869–1969
TL;DR: The first century of hypertrophic cardiomyopathy (HCM) is talked about and the experience during the last decades of this century is emphasized, which few people realize.
Journal ArticleDOI
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Robert J. Mentz,Jonathan H Ward,Adrian F. Hernandez,S Lepage,David A. Morrow,Samiha Sarwat,Kavita Sharma,Randall C. Starling,Eric J. Velazquez,Kristin M. Williamson,Akshay S. Desai,Shelley Zieroth,Scott D. Solomon,Eugene Braunwald +13 more
TL;DR: Paraglide-HF as discussed by the authors is a double-blind, randomized controlled trial of sacubitril/valsartan vs valsartan in patients with worsening heart failure (WHF) enrolled within 30 days of a WHF event.
Journal ArticleDOI
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Sarah E. Nelson,Robert P. Giugliano,Elliott M. Antman,Jeong-Gun Park,Andrew D. Norden,Natalia S. Rost,Scott B. Silverman,Aneesh B. Singhal,Hans Lanz,Eugene Braunwald,Christian T. Ruff,Investigators +11 more
TL;DR: In this article, the authors evaluated ICH characteristics and outcomes from Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48), a randomized trial that compared two edoxaban regimens (higher-dose EDoxaban regimen 60/30 mg (HDER), lower-dose edoxaba regimen 30/15 mg (LDER)) with warfarin in patients with atrial fibrillation.
Journal ArticleDOI
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit.
TL;DR: This review provides many different types of tools, including pathway documents, pocket cards, standardized order sets, posters, and personal digital assistant programs, all aimed to improve the quality of care provided to patients with ACS.
Journal ArticleDOI
Changing the practice of cardiovascular medicine
TL;DR: It is essential that clinicians be aware of the evidence base supporting early and aggressive treatment of patients with acute coronary syndromes and that this is communicated to all clinicians involved in their care of patientsWith acute coronary Syndromes.